
Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer - our goal is to fundamentally change the outcomes for these patients.
ThesmallmoleculeCMCteamisseekinghighlymotivatedSr. ScientistI ofAnalyticalDevelopmenttohelpbuildourdynamicsmallmolecule CMCgroupatAlumisThe successful candidate will help to support theanalytical development and quality control activities from the preclinical phase through late-stage clinical development. Having analytical developmentexpertise and experience in working with CMOs/CTLs, coupled with thoroughunderstanding of the associated quality and regulatory awareness are key assets.
RESPONSIBILITIES
THE IDEAL CANDIDATE
This position is located in South San Francisco, CA. At this time, we are not considering fully remote applicants.
The salary range for this position is $112,000 USD to $135,000 USD annually. This salary range is an estimate, and the actual salary may vary based on the Company’s compensation practices.
Alumis Inc. is an equal opportunity employer.
Alumis compensation packages include generous stock option grants for all employees as well as an annual bonus program.
Other benefits include:
We are a hard-working, collaborative team on a mission to transform patient’s lives-- and we aspire to elevate, challenge and nurture one another along the way.

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects.
Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction.
Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.